CU24583B1 - Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri) - Google Patents

Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)

Info

Publication number
CU24583B1
CU24583B1 CU2018000138A CU20180138A CU24583B1 CU 24583 B1 CU24583 B1 CU 24583B1 CU 2018000138 A CU2018000138 A CU 2018000138A CU 20180138 A CU20180138 A CU 20180138A CU 24583 B1 CU24583 B1 CU 24583B1
Authority
CU
Cuba
Prior art keywords
mri
metal oxide
magnetic resonance
contrast agents
oxide nanoparticles
Prior art date
Application number
CU2018000138A
Other languages
English (en)
Other versions
CU20180138A7 (es
Inventor
Martínez Alberto Bencomo
García Alicia Marcelina Díaz
Dalmau Evelio González
Rodríguez Andy Guzmán
Rodríguez Armando José Hernández
Mesa Claudia Iriarte
Chaviano Samila León
Quevedo Armando Augusto Paneque
Molina Israel Reyes
Marrero Suchitil Rivera
Izquierdo Julio Ricardo Rodríguez
Chryslaine Rodríguez-Tanty
Carrazana Marquiza Sablón
Menéndez Del Valle Roberto Soto
Original Assignee
Centro De Neurociencias De Cuba
Univ La Habana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Neurociencias De Cuba, Univ La Habana filed Critical Centro De Neurociencias De Cuba
Priority to CU2018000138A priority Critical patent/CU24583B1/es
Priority to JP2021525088A priority patent/JP7418429B2/ja
Priority to CN201980083238.6A priority patent/CN113226381B/zh
Priority to KR1020217017311A priority patent/KR20210091216A/ko
Priority to EP19750050.7A priority patent/EP3878475A1/en
Priority to PCT/CU2019/050005 priority patent/WO2020094161A1/es
Priority to BR112021008773-7A priority patent/BR112021008773A2/pt
Priority to US17/291,996 priority patent/US20210290782A1/en
Priority to MX2021005232A priority patent/MX2021005232A/es
Priority to CA3118959A priority patent/CA3118959A1/en
Publication of CU20180138A7 publication Critical patent/CU20180138A7/es
Priority to ZA2021/03859A priority patent/ZA202103859B/en
Publication of CU24583B1 publication Critical patent/CU24583B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

<p>Esta invención se relaciona con las ramas de Ia Química y Ia Física aplicadas a Ia medicina y se refiere a la obtención de nanopartículas de óxidos metálicos de fórmula general I,</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>cuyos sustituyentes R1, R2 y R3 están expuestos en la descripción y reivindicaciones. Estas nanopartículas magnéticas, recubiertas, funcionalizadas y conjugadas a compuestos naftalénicos afines a los aglomerados y placas ß-amiloides presentes en las enfermedades neurodegenerativas, atraviesan la barrera hematoencefálica (BHE) sin el empleo de ningún agente disruptor de membrana. Estos compuestos se utilizan en la detección temprana y no invasiva de aglomerados y placas amiloideas mediante la técnica de imagen por Resonancia Magnética (IRM) y son capaces de actuar como agentes de contraste para IRM en el diagnóstico temprano y no invasivo de la (EA).</p>
CU2018000138A 2018-11-06 2018-11-06 Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri) CU24583B1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU2018000138A CU24583B1 (es) 2018-11-06 2018-11-06 Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)
PCT/CU2019/050005 WO2020094161A1 (es) 2018-11-06 2019-05-13 Nanopartículas de óxidos metálicos conjugados con derivados de naftaleno en cuanto agentes de contraste para la detección de placas beta amiloides por imágenes de resonancia magnética
CN201980083238.6A CN113226381B (zh) 2018-11-06 2019-05-13 作为用于通过磁共振成像检测β-淀粉样斑的造影剂的与萘衍生物缀合的金属氧化物纳米粒
KR1020217017311A KR20210091216A (ko) 2018-11-06 2019-05-13 자기 공명 영상(MRI)에 의한 β-아밀로이드 플라크의 검출용 조영제로서 나프탈렌 유도체와 접합된 금속 산화물 나노입자
EP19750050.7A EP3878475A1 (en) 2018-11-06 2019-05-13 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of beta amyloid plaques by magnetic resonance images
JP2021525088A JP7418429B2 (ja) 2018-11-06 2019-05-13 磁気共鳴画像法（ＭＲＩ）によるβ－アミロイドプラークの検出のための造影剤としてのナフタレン誘導体と結合した金属酸化物ナノ粒子
BR112021008773-7A BR112021008773A2 (pt) 2018-11-06 2019-05-13 Nanoparatículas de óxidos metálicos conjugadas com derivados de naftaleno como agentes de contraste para a detecção de placas beta amiloides por imagens de ressonância magnética
US17/291,996 US20210290782A1 (en) 2018-11-06 2019-05-13 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of beta amyloid plaques by magnetic resonance images
MX2021005232A MX2021005232A (es) 2018-11-06 2019-05-13 Nanoparticulas de oxidos metalicos conjugados con derivados de naftaleno como agentes de contrastes para la deteccion de placas amiloides por resonancia magnetica (mri).
CA3118959A CA3118959A1 (en) 2018-11-06 2019-05-13 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of .beta.-amyloid plaques by magnetic renosance images (mri)
ZA2021/03859A ZA202103859B (en) 2018-11-06 2021-06-04 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of beta amyloid plaques by magnetic resonance images

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2018000138A CU24583B1 (es) 2018-11-06 2018-11-06 Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)

Publications (2)

Publication Number Publication Date
CU20180138A7 CU20180138A7 (es) 2020-10-20
CU24583B1 true CU24583B1 (es) 2022-02-04

Family

ID=67551036

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000138A CU24583B1 (es) 2018-11-06 2018-11-06 Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)

Country Status (11)

Country Link
US (1) US20210290782A1 (es)
EP (1) EP3878475A1 (es)
JP (1) JP7418429B2 (es)
KR (1) KR20210091216A (es)
CN (1) CN113226381B (es)
BR (1) BR112021008773A2 (es)
CA (1) CA3118959A1 (es)
CU (1) CU24583B1 (es)
MX (1) MX2021005232A (es)
WO (1) WO2020094161A1 (es)
ZA (1) ZA202103859B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20200087A7 (es) * 2020-11-24 2022-07-08 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
EP2285423B1 (en) * 2008-04-22 2020-03-18 MegaPro Biomedical Co., Ltd. Biocompatible polymer and magnetic nanoparticle with biocompatibility
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
CN105585614B (zh) * 2014-10-24 2019-06-07 中国科学技术大学 用于淀粉样蛋白显像的血管肽及其衍生物
TW201838658A (zh) * 2017-04-17 2018-11-01 香港中文大學 用於藉由磁振造影(mri)早期診斷阿兹海默症之奈米顆粒造影劑

Also Published As

Publication number Publication date
WO2020094161A1 (es) 2020-05-14
KR20210091216A (ko) 2021-07-21
BR112021008773A2 (pt) 2021-10-26
CU20180138A7 (es) 2020-10-20
JP2022515706A (ja) 2022-02-22
MX2021005232A (es) 2021-08-11
CN113226381B (zh) 2023-09-19
US20210290782A1 (en) 2021-09-23
CN113226381A (zh) 2021-08-06
ZA202103859B (en) 2022-07-27
CA3118959A1 (en) 2020-05-14
EP3878475A1 (en) 2021-09-15
JP7418429B2 (ja) 2024-01-19

Similar Documents

Publication Publication Date Title
CY1124113T1 (el) Συνθεσεις και μεθοδοι για την θεραπευτικη αντιμετωπιση διαταραχων κνς
CY1124112T1 (el) Νευροδραστικα στεροειδη, συνθεσεις, και χρησεις αυτων
CY1124241T1 (el) Ανοσορρυθμιστες ρετ-απεικονισης
CY1124330T1 (el) Νευροδραστικα στεροειδη, συνθεσεις, και χρησεις αυτων
CR20180307A (es) Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer
CY1120172T1 (el) Αναστολεις κινασων σερινης/θρεονινης
CL2019002461A1 (es) Arn terapéutico.
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CL2016001447A1 (es) Uso de una solución acuosa de clorhexidina (&lt;1%) para la preparación de un medicamento o dispositivos medicos de aplicación, para reducir la infección en un sujeto, en la sangre, tracto urogenital, tracto respiratorio, sitio intraperitoneal, colon, senos nasales, sitio intra-articular, en el mediastino o un sitio cerebroespinal.
UY35147A (es) Anticuerpos anti-ceacam5 y usos de éstos.
SV2016005312A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer
CO6400172A2 (es) C5ar antagonistas
GT201500348A (es) Compuestos de pirimidinodiona contra estados cardíacos
CO2023012137A2 (es) Nuevo agente de contraste para utilizar en imágenes por resonancia magnética
NI201600022A (es) Compuestos terapéuticamente activos y sus métodos de uso
NI201500093A (es) Modulador del receptor de andrógenos y usos de este
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CU24583B1 (es) Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)
CU20150006A7 (es) Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato útiles como antagonistas del receptor -h3
CY1123955T1 (el) [8-(φαινυλοσουλφονυλο)-3,8-διαζαδικυκλο[3.2.1]οκτ-3-υλο](1η-1,2,3-τριαζολο-4-υλο)μεθανονες
BR112018076389A2 (pt) composto, método para preparação de um composto, e, composição farmacêutica.